July 23, 2017 1:50 AM ET


Company Overview of RadioMedix, Inc.

Company Overview

RadioMedix, Inc., a biotechnology company, develops and commercializes radiopharmaceuticals for diagnosis and therapy of cancer and automated processing modules. Its portfolio includes technologies and products, which enable on-site and on-demand access to Positron Emission Tomography (PET). Its technologies include GlucoMedix, a 68Ga-labeled carbohydrate analogue for PET imaging; GluTracer-68 that improves 18F-FDG images; OncoTracer, which provides information about tumor attributes, which are lacking with current PET tracers; and SyntheMedix, an automated radiopharmaceutical synthesis system developed for the production of generator-based PET radiotracers. The company was founded in 2006 a...

9701 Richmond Avenue

Suite 222

Houston, TX 77042

United States

Founded in 2006





Key Executives for RadioMedix, Inc.

Founder, Chief Executive Officer and President
Chief Operating Officer
Chief Technology Officer
Director of Chemical Research & Drug Development
Regulatory Consultant
Compensation as of Fiscal Year 2017.

RadioMedix, Inc. Key Developments

RadioMedix, Excel Diagnostics and Nuclear Oncology Center, and the Ahmanson Translational Imaging Division for Phase II Prostate Cancer Trial Receive FDA Clearance

RadioMedix, Excel Diagnostics and Nuclear Oncology Center (EDNOC), and the Ahmanson Translational Imaging Division at the David Geffen School of Medicine at UCLA have received the FDA clearance to their investigational new drug (IND) application for their Phase II clinical trial for the use of 177Lu-PSMA-617 for targeted Radioligand Therapy (RLT) in patients with castration-resistant prostate cancer. This will be the first prospective clinical trial in the US with prostate specific membrane antigen (PSMA) directed radioligand therapy providing new treatment options for patients with advanced, castration resistant prostate cancer. ABX's proprietary ligand PSMA-617 and ITG Isotope Technologies Garching's EndolucinBeta (no-carrier added 177Lu) used in this Radioligand Therapy are unique features of this highly avid and environmentally friendly RLT compound".

RadioMedix Inc. and AREVA Med Receives Contract Grant to Develop Targeted Alpha-Emitter Therapy of Neuroendocrine Tumors with Lead-212

RadioMedix Inc. and AREVA Med announced that they have been awarded a collaborative Small Business Innovation Research (SBIR) Contract Grant by the National Institutes of Health, National Cancer Institute to evaluate targeted alpha-emitter therapy of neuroendocrine tumors (NETs). This is the fourth NIH grant awarded to RadioMedix during the last three years. Targeted Peptide Receptor Radio Therapy (PRRT) of NETs is one of the main clinical focuses of RadioMedix, which has long been involved in several clinical studies as a co-sponsor or a collaborator. AREVA Med is focused on the production of lead-212 (212Pb), a rare metal used in TAT, and the development of therapeutics using this metal.

RadioMedix Inc. Completes the Phase I/ II Clinical Studies for AminoMedix ™

RadioMedix Inc. announce the completion of the Phase I/II clinical trial of AminoMedix ™ proprietary formulation used for kidney radioprotection during PRRT. Kidneys are dose-limiting organs during the Peptide Receptor Radionuclide Therapy (PRRT) due to reabsorption of radiotherapeutic agents in the kidneys. Due to the lack of an FDA approved compound to protect kidneys during PRRT, currently different solutions of amino acids are being used, off-labeled, in the clinics. While the co-administration of these megalin-targeting compositions, decrease the accumulation of nephrotoxic radiopeptides in renal proximal tubular cells, it also may lead to severe side effect, including grade 3 or 4 hyperkalemia and severe nausea and vomiting. RadioMedix Phase I/II clinical trials confirmed the correct dose of the components of AminoMedix ™ and also presented both safety and effectiveness of AminoMedix ™ composition in reducing kidney radiation absorbed dose while preventing clinically significant hyperkalemia, nausea and vomiting, during PRRT. RadioMedix has completed the dose optimization of AminoMedix ™ formulation and the company is in the process of scaling up of GMP manufacturing and stability studies of AminoMedix ™ for its centralized distribution plan.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact RadioMedix, Inc., please visit www.radiomedix.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.